Completed PHASE3 INTERVENTIONAL 3-arm NCT01825031

Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy (REALITY)

Reduction of Early mortALITY in HIV-infected African Adults and Children Starting Antiretroviral Therapy: a Randomised Controlled Trial

Sponsor: Anna Griffiths, MRC

Conditions Human Immunodeficiency Virus

Interventions Albendazole Azithromycin Fluconazole Isoniazid Raltegravir Ready to Use Supplementary Food

Updated 5 times since 2017 Last updated: Apr 19, 2016 Started: Jun 30, 2013 Primary completion: Mar 31, 2016 Completion: Mar 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01825031, this PHASE3 trial focuses on Human Immunodeficiency Virus and remains completed. Sponsored by Anna Griffiths, MRC, it has been updated 5 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Anna Griffiths, MRC
Department for International Development, United Kingdom
Medical Research Council
PENTA Foundation
Wellcome Trust

Data source: Medical Research Council

For direct contact, visit the study record on ClinicalTrials.gov .

Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy (REALITY)

Status Flow

Change History

Eligibility Summary

Contact Information

Study Locations

Related Trials